CD：又破除一个免疫治疗耐药壁垒！科学家发现，敲除STAT3能逆转STK11突变型非小细胞肺癌对双免疫联合治疗的耐药丨科学大发现
Sohu News,
阻断免疫检查点通路的免疫疗法（CPI）已被批准用于包括非小细胞肺癌（NSCLC）在内的众多肿瘤适应症的临床治疗 [1] 。然而，目前只有约一半的患者从中获益，其余患者则对CPI产生了不同类型的耐药性，包括原发性、适应性和获得性耐药。 由于CPI复杂的抗癌机制…
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Overview of attention for article published in Journal of Thoracic Oncology, June 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (85th percentile)
-
Good Attention Score compared to outputs of the same age and source (66th percentile)
Mentioned by
- news
- 1 news outlet
- 1 X user
- 1 Redditor
- guideline
- 1 clinical guideline source
Readers on
- mendeley
- 90 Mendeley